Embedded Files
Europe Biosimilar Market 2025-2033
According to IMARC Group's report titled "Europe Biosimilar Market Report by Molecule (Infliximab, Insulin Glargine, Epoetin Alfa, Etanercept, Filgrastim, Somatropin, Rituximab, Follitropin Alfa, Adalimumab), Indication (Auto-Immune Diseases, Blood Disorder, Diabetes, Oncology, Growth Deficiency, Female Infertility), Manufacturing Type (In-house Manufacturing, Contract Manufacturing), and Country 2025-2033", the report presents a thorough review featuring the market share, growth, share, trends, and research of the industry.
How Big is the Europe Biosimilar Industry?
The Europe biosimilar market size was valued at USD 13,864 Million in 2024 and is projected to grow to USD 59,733.3 Million by 2033, with an expected compound annual growth rate (CAGR) of 17.1% from 2025 to 2033.
Europe Biosimilar Market Trends:
The market in Europe is largely fueled by the surging demand for affordable treatment alternatives among patients who are suffering chronic illnesses. In accordance with this, the increase in the number of biologic drugs that are nearing patent expiry is expected to increase the production of biosimilars, which would further enhance the growth of the market. In addition, the improving health care infrastructure throughout the area is going to allow for the wider adoption of biosimilars with encouragement from favorable regulatory frameworks. Moreover, the spiraling health expenditure in Europe is empowering both patients and providers to consider biosimilars as viable.
Additionally, the rising emphasis on the health care cost has stimulated the market growth of biosimilars, which offer considerable savings without compromising effectiveness, thereby propelling the market. Furthermore, increasing government bodies' and health organizations' support for biosimilar development also contribute significantly to stimulating growth. The increasing awareness campaigns about biosimilars' safety and efficiency give more chances for acceptance among healthcare professionals and patients. Increasing investments by pharmaceutical companies in biosimilar R&D would further enhance the market for innovation and competition.
For an in-depth analysis, you can refer free sample copy of the report: https://www.imarcgroup.com/europe-biosimilar-market/requestsample
Europe Biosimilar Market Scope and Growth Analysis:
The scope of the market is changing considerably with increasing therapeutic applications in treating unmet clinical needs in oncology, immunology, and endocrinology. Furthermore, with increasing acceptability of biosimilars in hospital settings, these biosimilars are integrating into hospitals' treatment protocols, thus strengthening the market. Another factor is providing access to biosimilar drugs at low rates in a way that would promote equitable access to advanced therapies, especially in developing economies in Europe. Moreso, regulatory authorities and pharmaceutical companies have worked in good collaboration to grant approval on time while hastening product launches.
The presence and growth of local manufacturers are also diversifying the market by catering to regional requirements and preferences. The use of advanced manufacturing technologies enhances production efficiency, reduces costs, and makes the supply chain dynamic. Besides promoting interchangeability, this has similarly provided prescribers with confidence to accept biosimilars, therefore, bolstering demand. Also, recent market analysis reveals how the changing reimbursement policies have enhanced biosimilar uptake and are affecting the market outlook by more favourably positioning industry stakeholders and the healthcare system.
Ask Analyst For Customization: https://www.imarcgroup.com/request?type=report&id=1023&flag=C
By the IMARC Group, the Top Competitive Landscapes Operating in the Industry:
Novartis
Pfizer
Teva
Celltrion
Merck Sharp & Dohme
Samsung Bioepis
Eli Lilly
Accord Healthcare Ltd.
Amgen
Boehringer Ingelheim
Hexal Ag
Apotex
Stada Arzneimittel Ag
Ratiopharm
Mylan
Europe Biosimilar Market Segmentation:
The market report offers a comprehensive analysis of the segments, highlighting those with the largest Europe biosimilar market share. It includes forecasts for the period 2025-2033 and historical data from 2019-2024 for the following segments.
Breakup by Molecule:
Infliximab
Insulin Glargine
Epoetin Alfa
Etanercept
Filgrastim
Somatropin
Rituximab
Follitropin Alfa
Adalimumab
Breakup by Indication:
Auto-Immune Diseases
Blood Disorder
Diabetes
Oncology
Growth Deficiency
Female Infertility
Breakup by Manufacturing Type:
In-house Manufacturing
Contract Manufacturing
Breakup by Country:
Italy
Germany
United Kingdom
France
Spain
Rest of Europe
Key highlights of the Report:
Market Performance (2019-2024)
Market Outlook (2025-2033)
COVID-19 Impact on the Market
Porter’s Five Forces Analysis
Strategic Recommendations
Historical, Current and Future Market Trends
Market Drivers and Success Factors
SWOT Analysis
Structure of the Market
Value Chain Analysis
Comprehensive Mapping of the Competitive Landscape
Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us:
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services.
IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
Page updated
Google Sites
Report abuse